Cat. No. | Product name | CAS No. |
DC7501 |
SKLB1002
Featured
SKLB1002 is a novel and potent VEGFR-2 inhibitor with an IC50 value of 32 nM. |
1225451-84-2 |
DC7502 |
SKLB610
Featured
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays. |
1125780-41-7 |
DC9992 |
Src kinase inhibitor I
Featured
Src kinase inhibitor I is a potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes. |
179248-59-0 |
DC10600 |
SU 5205
Featured
SU 5205 is a VEGFR2 inhibitor. |
3476-86-6 |
DC10519 |
SU 5214
Featured
SU 5214 is a modulator of tyrosine kinase signal transduction. |
186611-04-1 |
DC9794 |
SU-10994
SU-10994 is a novel VEGFR inhibitor. |
|
DC1093 |
SU11274 (PKI-SU11274)
Featured
SU11274 is a selective Met inhibitor with IC50 of 10 nM. |
658084-23-2 |
DC7302 |
SU14813
Featured
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3). |
627908-92-3 |
DC7509 |
SU1498
Featured
SU1498 is a selective inhibitor of the VEGFR2; inhibits Flk-1with an IC50 of value of 700 nM. |
168835-82-3 |
DC9781 |
SU4312(NSC86429)
Featured
SU4312(NSC86429) is a selective, cell-permeable inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively). |
5812-07-7 |
DC7508 |
SU 5402
Featured
SU5402(SU-5402; SU5402) is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively). |
215543-92-3 |
DC5079 |
Orantinib (TSU-68)
Featured
SU6668 has greatest potency against PDGFR autophosphorylation with Ki of 8 nM, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. |
252916-29-3 |
DC10271 |
SUN11602
Featured
SUN11602 is a novel aniline compound, which mimics the neuroprotective mechanisms of basic fibroblast growth factor. |
704869-38-5 |
DC3145 |
Sunitinib base
Featured
Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. |
557795-19-4 |
DC3146 |
Sunitinib malate
Featured
Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. |
341031-54-7 |
DC7885 |
NVP-TAE226
Featured
TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. |
761437-28-9 |
DC7057 |
TAK-285
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. |
871026-44-7 |
DC10523 |
TAK-659 HCl
Featured
TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM. |
1952251-28-3 |
DC10065 |
Takeda-6d
Featured
Takeda-6d has potent inhibitory activity in both B-RAF with an IC50 of 7.0 nM and VEGFR2 with an IC50 of 2.2 nM. |
1125632-93-0 |
DC7894 |
Tandutinib(MLN518)
Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2. |
387867-13-2 |
DC12256 |
TAS-115 mesylate (TAS-115 methanesulfonate)
Featured
TAS-115 mesylate is a potent VEGFR and c-Met/HGFR kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. |
1688673-09-7 |
DC8376 |
TAS-301
Featured
TAS-301 is an inhibitor of smooth muscle cell migration and proliferation. |
193620-69-8 |